On Friday, Humacyte Inc (NASDAQ: HUMA) opened higher 18.52% from the last session, before settling in for the closing price of $1.89. Price fluctuations for HUMA have ranged from $1.15 to $9.97 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 84.69% at the time writing. With a float of $125.75 million, this company’s outstanding shares have now reached $155.12 million.
Let’s determine the extent of company efficiency that accounts for 220 employees. In terms of profitability, gross margin is 23.12%, operating margin of -1433.23%, and the pretax margin is -1002.79%.
Humacyte Inc (HUMA) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Humacyte Inc is 18.94%, while institutional ownership is 39.72%. The most recent insider transaction that took place on Apr 14 ’25, was worth 9,999. In this transaction Chief Commercial Officer of this company bought 6,493 shares at a rate of $1.54, taking the stock ownership to the 22,018 shares. Before that another transaction happened on Apr 10 ’25, when Company’s CFO and Chief Corp. Deve. Off. bought 20,000 for $1.53, making the entire transaction worth $30,600. This insider now owns 40,600 shares in total.
Humacyte Inc (HUMA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 84.69% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Check out the current performance indicators for Humacyte Inc (HUMA). In the past quarter, the stock posted a quick ratio of 3.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 668.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.69, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Looking closely at Humacyte Inc (NASDAQ: HUMA), its last 5-days average volume was 7.98 million, which is a jump from its year-to-date volume of 3.56 million. As of the previous 9 days, the stock’s Stochastic %D was 86.67%. Additionally, its Average True Range was 0.20.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 19.40%, which indicates a significant decrease from 98.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 142.68% in the past 14 days, which was higher than the 132.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.92, while its 200-day Moving Average is $4.31. However, in the short run, Humacyte Inc’s stock first resistance to watch stands at $2.40. Second resistance stands at $2.57. The third major resistance level sits at $2.87. If the price goes on to break the first support level at $1.93, it is likely to go to the next support level at $1.63. Should the price break the second support level, the third support level stands at $1.46.
Humacyte Inc (NASDAQ: HUMA) Key Stats
There are currently 155,119K shares outstanding in the company with a market cap of 347.47 million. Presently, the company’s annual sales total 0 K according to its annual income of -148,700 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -20,940 K.
